Date: 2012-03-28
Type of information: IPO
Company: DBV Technologies (France)
Investors: The French Strategic Investment Fund (Fonds stratégique d\'investissement - FSI) has taken a stake in DBV Technologies by investing 15 € million euros as part of the offer. The FSI is holding 12.6%% of its capital.
Amount: €40.5 million
Funding type: initial public offering (IPO)
Planned used: DBV Technologies will use these funds to finance and develop its strategy in the field of allergy, especially food allergy. Three products are currently in clinical development. Peanut Viaskin ® for the treatment of peanut allergy in adults and children, has entered Phase II in France in 2010. Two other studies are to be launched in 2013: a phase II study with Viaskin Milk ® for allergy to cow\'s milk in children and a phase I study with HDM Viaskin ® for dust mite allergy in children.
Others: DBV Technologies has successfully completed its initial public offering (IPO) on NYSE Euronext in Paris raising a total proceed of €4 0.5 million. The price of the offering was settled at € 8.86 per share.
Therapeutic area: Allergic diseases - Immunological diseases
